Phase 2 Multiple Sclerosis Trial, By Invitation NCT05957913 Sponsor: Massachusetts General Hospital Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, By Invitation

NCT05957913
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are willing and able to sign and date a consent form agreeing to take part in the study.
  • People who are willing and able to follow all study procedures and are available for the full duration of the study.
  • People who are 18 years of age or older.
  • People who have been diagnosed with multiple sclerosis.
  • People who have evidence of a past Epstein-Barr virus (EBV) infection, shown through a blood test for EBV antibodies (this testing can be done at the pre-screening visit, but people whose results come back negative will be removed from the study).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are pregnant or breastfeeding.
  • People who have a known allergy to any ingredient in the medication Truvada.
  • People who have previously been treated with Truvada or Descovy.
  • People whose HIV status is unknown — blood tests for HIV must have been completed either within the past 6 months or at the pre-screening visit.
  • People who have active or past (latent) hepatitis B infection — specific hepatitis B blood tests must have been completed either within the past 6 months or at the pre-screening visit.
  • People who currently have severe, uncontrolled, or worsening problems with their kidneys, blood, digestive system, lungs, heart, or nervous system, or other conditions that the study doctor believes would put them at unacceptable risk.
  • People whose kidney filtering function is below a certain level, as measured by a calculation called the Cockcroft-Gault equation (confirm with trial site for exact threshold).
  • People whose urine test shows certain levels of protein or glucose (confirm with trial site for exact threshold).
  • People with a history of bone fractures that were not caused by an injury or accident.
  • People with low phosphate levels in the blood at a moderate or higher level of severity (confirm with trial site).
  • People who have any moderate or more serious abnormal results on screening tests (confirm with trial site).
  • People who are currently taking medications known to interact with Truvada, including but not limited to: acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple anti-inflammatory pain relievers (NSAIDs) or regular high doses of NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect kidney function.
  • People who are currently taking medications known to affect Epstein-Barr virus activity, including: acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, or interferon.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 June 2023
Est. completion
4 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Epstein Barr virus (EBV) viral load

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov